MORRISVILLE, N.C. — Sales of its AIDS drug Fuzeon surged 23 percent in North America in the second quarter,
Trimeris
(Nasdaq: TRMS) said Wednesday.
U.S. and Canada sales hit $31.1 million for the quarter ending June 30.
Global sales totaled $57.2 million, up 6 percent for the same time period in 2005. The increase came despite the fact that Brazil, which makes bulk purchases of Fuzeon on an intermittent basis, did not make a purchase in the quarter, according to a Trimeris spokesperson.
Sales are recorded by Roche, Trimeris' partner in production of Fuzeon.
Copyright 2024 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
